Transurethral Intraprostatic Botulinum Toxin-a Injection in Patients with Benign Prostatic Hyperplasia: A Case Series and Literature Review
We aimed to assess the efficacy of Intraprostatic Onabotulinumtoxin-A (BTA) on the International Prostate Symptom Score (IPSS) and other objective measures of patients with Benign Prostatic Hyperplasia (BPH).
Fifteen patients were included in this study. The drug (BTA; 150 IU) was reconstituted in 20 mL of 0.9% saline before administration to the patients. After providing urethral anesthesia, 20 intraurethral injections were made to lateral lobes of the prostate, 10 injections in each lobe. Follow-up visits were planned 3 and 12 months after the intervention. Pre- and post-interventional IPSS, Prostate-Specific Antigen (PSA), Prostate Volume (PV), Post-Void Residue (PVR), and maximum urinary flow rate (Qmax) compared via paired t-test. Finally, we reviewed the Pubmed database to provide a more precise conclusion.
The Mean±SD age of patients was 69±8.24 years, and the mean IPSS score decreased significantly from 24.3±3.3 to 14.6±3.7 (p<0.001) and 16.86±3.06 (p<0.009) on the 3rd and 12th months, respectively. The Mean±SD PSA, PVR, Qmax, and PV were 3.26±1.38, 82.33±35.55, 8.56±1.76, and 47.86±8.93, respectively at baseline. These factors significantly improved to 2.72±1.33 (P<0.000), 71.33±30.55 (p<0.000), 9.5±1.33 (p<0.011), and 42.86± 6.04 (p<0.000), respectively, on the 12th month follow-up.
Although the overall results support the efficacy of BTA for BPH, the best route of administration, the most effective dose, the optimal number, and the volume of injections need further investigations. The probable placebo effect and underlying medical conditions (e.g., insulin resistance) should be considered as the confounding factors.
-
Second primary cancer prevalence in differentiated thyroid cancer patients and correlation with thyroid primary tumor stage: A population-based cohort study in Iran
Sajjad Sadeghpour, Seyed Rasoul Zakavi, Emran Askari, Forough Kalantari, Reza Karimi, Zakieh Nasiri, Susan Shafiei, Ehsan Soltani, *, Amin Doostparast
Iranian Journal of Nuclear Medicine, Winter-Spring 2025 -
Evaluation of response to radioiodine therapy in thyroid oncocytic carcinoma patients: A single center experience from Iran
*, Forough Kalantari, Seyed Rasoul Zakavi, Emran Askari, Ehsan Soltani, Farivash Karamian, Somayeh Barashki, Kayvan Sadri, Narges Akbari, Zahra Fazeli
Iranian Journal of Nuclear Medicine, Winter-Spring 2025 -
Evaluation of Clinicopathologic Characteristics and Survival Rates of Patients with Renal Cell Carcinoma in Northeast of Iran
Ali Taghizadeh Kermani, Ali Emadi Torghabeh, Mahshidsadat Chenarani Moghadam, Mona Joudi, Lida Jarahi, , Alireza Ghoreifi
International Journal of Cancer Management, Dec 2024 -
Evaluating the Correlation Between Serum PSA Values and Gleason Score of Prostate Carcinoma with Ga68-PSMA Uptake in Prostate Tumor in Primary Staging
, Salman Soltani, , Mona Kabiri, Nooshin Tafazoli, Habibollah Dadgar, Zahra Bakhshi Golestani, Nasim Norouzbeigi, Vahidreza Dabbagh, Ramin Sadeghi, Amir Momeni *
Journal of Translational Research in Urology, Spring 2024 -
Synergistic Effect of Curcumin on Controlling Irritative Urinary Symptoms After Benign Prostatic Enlargement Endoscopic Surgery Compared with Anticholinergic Therapy Alone
Salman Soltani, Sahar Dabbaghian, Mahmoud Tavakoli, , Sepehr Sadr, Sahar Shahbazi, Kamyar Tavakoli Tabasi, Maryam Emadzadeh, Sajjad Sadeghpour, *
Journal of Translational Research in Urology, Autumn 2023 -
Diagnostic Accuracy of Intra-Abdominal Pressure Measurement Method via Bladder in Predicting Renal Dysfunction after Kidney Transplantation
Mahtab Torkamani, Nahid Aghebati *, Hamid Heidarian Miri, Mahmoud Tavakoli, Ahmad Farid Ejaz
Evidence Based Care, Autumn 2021